Fluifort syrup 9% 120ml vial with a metering cup

Description

Composition
Active substance:
carbocisteine ​​lysine monohydrate (based on lysine karbotsistein) 9.0 g
Excipients:
sucrose 40.00 g, cherry flavor, 0.25 g, 0.15 g of methyl parahydroxybenzoate, 0.03 g of caramel, purified water to 100 ml.
Description:
The clear solution was dark yellow color with a characteristic smell of cherries.
Product form:
120 ml vial.
Contraindications
Hypersensitivity to any component of the drug. Gastric ulcer and duodenal ulcer (in the acute stage). Pregnancy (I term) and during breastfeeding. Children under 1 year.
The drug should not be taken by patients with hereditary disorders such as galactose malabsorption of glucose, or sucrase-isomaltase insufficiency.
Dosage
90 mg / ml
Indications
Acute and chronic bronchopulmonary disease, accompanied by the formation of a viscous and sputum (tracheitis, bronchitis, tracheobronchitis, bronchial asthma, bronchiectasis) and mucus (inflammatory disease of middle ear and sinuses – rhinitis, adenoids, otitis media, sinusitis), of patient preparation for bronchoscopy or bronhografii.
Interaction with other drugs
There were no interactions carbocisteine ​​and foodstuffs, as well as substances used for laboratory studies.
Antitussive effect is weakened and m-anticholinergic drugs.
Enhances effectiveness of glucocorticoids (mutually) and antibiotic therapy of infectious and inflammatory diseases of the upper and lower respiratory tract.
Enhances the bronchodilator effect of theophylline.
Overdose
Symptoms: skin reactions, gastrointestinal disorders and sensory system disorders.
Measures to assist in overdose
There is no specific antidote. Recommended gastric lavage and specific maintenance therapy
pharmachologic effect
Pharmacological group:
expectorant mucolytic agent
Pharmacodynamics:
Carbocisteine ​​lysine salt restores viscosity and elasticity of mucous secretion upper and lower respiratory tract. The effect is dose-dependent.
Mucolytic and expectorant action carbocisteine ​​caused by activation of the lysine salt of sialic transferase (enzyme goblet cells of the bronchial mucosa). Normalizes the proportion of acidic and neutral mucins bronchial secretions: it reduces the number of neutral glycopeptides increases the amount gidroksisialoglikopeptidov. Reduces the viscosity of bronchial secretions and detachable from the paranasal sinuses, facilitating expectoration of mucus and reduces cough. Promotes regeneration of the mucosa, normalizes its structure, reduces the number of goblet cells, particularly in the terminal bronchi and, consequently, reduce the production of mucus. Restores the secretion of immunologically active IgA (specific protection), improves mucociliary clearance of antibiotics and transportation.
Furthermore, carbocisteine ​​lysine salt stimulates the secretion of chloride ions in the airway epithelium. This phenomenon is associated with the transport of water and thus dilution with mucous secretion. Carbocisteine ​​lysine salt increases the concentration of lactoferrin, lysozyme and alpha-1-antitrypsin, indicating functional recovery of mucosal cell bronchial glands and their mechanism of protein synthesis.
Carbocisteine ​​lysine salt compound is neutral (pH 6.8), well soluble in water and therefore does not irritate the gastric mucosa, which allows to assign the daily dose in one portion.
Pharmacokinetics:
Rapidly and almost completely absorbed after oral administration. Bioavailability carbocisteine ​​lysine salt is low (less than 10% of the dose) and do not depend on the dosage form. Cmax Maximum concentration in blood and in the mucosa is achieved after 1.5 – 2 h. Plasma half-life is 2-3 hours. As with all derivatives locked tioliticheskoy group carbocisteine ​​lysine salt has the greatest affinity for bronchopulmonary tissue. The drug concentration in the medium reaches the mucous 3.5 ug / ml with a half-life of about 1.8 hours (2 g daily dose). Complete removal occurs after 3 days.
Excretion is carried out mainly by the kidneys. Part of the drug is excreted by the kidneys in unchanged form (30 – 60%), the remainder is output in the form of metabolites.
Pregnancy and breast-feeding
Do not use this drug in 1 trimester of pregnancy and during breastfeeding.
Conditions of supply of pharmacies
Children older than 2 years and adults the drug available without a prescription.
side effects
The experience gained using Fluiforta, indicating that side reactions occur very rarely (frequency
Disorders of the skin and subcutaneous tissues: skin rashes, hives, erythema, bullous rash / erythema, pruritus, angioedema, dermatitis.
Disorders of the gastrointestinal tract: abdominal pain, nausea, vomiting, diarrhea.
Disorders of the nervous system: dizziness.
Violations of the cardiovascular system: flushing.
Violations of the respiratory system: dyspnea.
All of these disorders are transient and disappear after discontinuation of the drug or after dosage reduction.
If you experience any side effects, stop taking the drug and consult a doctor.
special instructions
Application Fluiforta does not lead to occurrence of metabolic dependence or addiction.
The preparation contains methyl parahydroxybenzoate, which may cause hives.
The drug has no effect on low-calorie diets and controlled, and can also be used in diabetic patients.
Patients with diabetes must take into account that 1 tablespoon syrup contains 6 g sucrose.
Impact on the management of vehicles and mechanisms
The drug has no effect on ability to drive and engage in other potentially hazardous activities that require concentration and speed of psychomotor reactions.
Storage conditions
At temperatures above 25 ° C.
Keep out of the reach of children!
Dosing and Administration
Inside. The pack is attached measuring cup graduated, according to the recommended doses.
Babies from 1 to 5 years: 2.5 ml syrup (225 mg) – 2-3 times per day.
Children older than 5 years: 5 ml syrup (450 mg) – 2-3 times per day.
Adults: 15 ml syrup (1.35 g) – 2-3 times per day.
The duration of treatment is determined by the doctor (from 4 days to 6 months).
Said dosage is stored for patients with impaired liver function and kidney disease, and patients suffering from diabetes.
For the opening of the vial strongly to press down on the cap and turn counterclockwise. After applying again tightly wrap cap
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist